Top-line Phase 2 results of MN-001 (Taipercast) showed a significant reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Safety was favorable. Further large-scale trials to evaluate efficacy will continue. No impact on consolidated results for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"MediciNova, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4875-20260928-01.pdf","jir_short_summary":"Top-line Phase 2 results of MN-001 (Taipercast) showed a significant reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Safety was favorable. Further large-scale trials to evaluate efficacy will continue. No impact on consolidated results for the fiscal year ending December 2026.","jir_summary":"### Study Overview and Key Results\nThis was a multicenter, randomized, double-blind, placebo-controlled proof-of-concept trial in which 40 subjects received MN-001 (500 mg\/day) or placebo for 24 weeks. The trial demonstrated an early reduction in TG, significant increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight, while the TG reduction difference at 24 weeks was not statistically significant. Safety was generally favorable.\n\n### Outlook and Impact\nThis trial was an exploratory POC study; going forward, efficacy will be evaluated in larger clinical trials. The company will continue to consider appropriate patient populations, endpoints, and sample sizes for the next phase. It is explicitly stated there is no impact on consolidated results for the fiscal year ending December 2026.","jir_financial_highlights":"Reduction in serum triglycerides (TG): At 4 weeks: MN-001 group decreased by 54.7 mg\/dL; placebo group decreased by 23.8 mg\/dL (Difference from baseline decrease: 30.96 mg\/dL (statistically significant: p=0.015))\nReduction in serum triglycerides (TG) at 24 weeks: MN-001 group decreased by 45.8 mg\/dL; placebo group decreased by 14.4 mg\/dL (Difference was 31.4 mg\/dL (not statistically significant: p=0.113))\nReduction in liver fat content (CAP score): MN-001 group decreased by 14.1 dB\/m; placebo group decreased by 4.3 dB\/m (Difference was 9.7 dB\/m (not statistically significant: p=0.2438))\nSerum HDL cholesterol (HDL-C): At 24 weeks MN-001 group +3.3 mg\/dL; placebo group -2.4 mg\/dL (Difference was 5.7 mg\/dL (statistically significant: p=0.0048))\nSerum HDL particle concentration (HDL-P): MN-001 group +3.62 \u00b5mol\/L; placebo group -0.9 \u00b5mol\/L (Difference was 4.52 \u00b5mol\/L (statistically significant: p=0.018))\nBody weight: MN-001 group -4.91 lb; placebo group -0.55 lb (Difference was -4.36 lb (not statistically significant: p=0.082))","jir_category":"","jir_hashtags":"#MediciNova, #LipidMetabolism, #NAFLD, #ClinicalTrialTopLine","jir_key_figures":"Difference in TG reduction at 4 weeks: 30.96 mg\/dL\nDifference in HDL-C increase at 24 weeks: 5.7 mg\/dL (p=0.0048)\nDifference in HDL-P increase at 24 weeks: 4.52 \u00b5mol\/L (p=0.018)","jir_meta_title":"MediciNova Announces MN-001 Phase 2 Top-line Results | September 2026","jir_meta_description":"MediciNova, Inc. discloses top-line results from the Phase 2 trial of MN-001. Reported findings include TG reduction, increases in HDL-C and HDL-P, and trends toward improvement in liver fat content and body weight. Analysis and future development plans toward larger trials. September 28, 2026","jir_og_title":"MediciNova MN-001 Phase 2 Top-line Results | September 2026","jir_og_description":"Announced top-line Phase 2 results for MN-001, reporting TG reduction, HDL-C increase, and trend toward improved liver fat content. Future evaluation in larger trials planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-123959","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n